88results about "Phosphorus-oxygen lyases" patented technology

The present disclosure relates to recombinant microorganisms, such as bacteria, e.g., E. coli, engineered to have improved flux and / or yield of the DXP pathway. Cells can be engineered to comprise nucleotide sequences comprising dxs polypeptides (EC 2.2.1.7); dxr polypeptides (EC 1.1.1.267); ispD polypeptides (EC 2.7.7.60); ispE polypeptides (EC 2.7.1.148); ispF polypeptides (EC 4.6.1.12); ispG polypeptides (EC 1.17.7.1 or EC 1.17.7.3); ispH polypeptides (EC 1.17.7.4); and idi polypeptides (EC 5.3.3.2). Cells can be further engineered to express redox polypeptides, e.g., ferredoxins, flavodoxins, and / or flavodoxin / ferredoxin--NADP reductases (EC 1.19.1.1 or EC 1.18.1.2), e.g., to increase the activity of the ispG and / or ispH polypeptides. Some or all of the nucleotide sequences can be heterologous to the cells. The recombinant microorganisms can be used in methods of isoprenoid production.

The invention relates to application of a gene pmtA in improving broad-spectrum tolerance of escherichia coli. According to the present invention, the research results show that the codon-optimized (derived from Rhodobacter sphaeroids) gene pmtA for coding phosphatidyl ethanolamine-N-methyltransferase EC 2.1. 1.17 is integrated to the escherichia coli genome ldhA site, such that phosphatidylcholine can be introduced to remodel the escherichia coli cell membrane phospholipid system so as to improve the broad-spectrum tolerance of escherichia coli; in addition, an artificial regulation element M1-12 and a gene pmtA are assembled to construct a tolerance module, and the tolerance module is integrated to a lactic dehydrogenase encoding gene ldhA site of an escherichia coli genome through a lambda Red homologous recombination method to obtain an engineering bacterium named + PC. According to the engineering strain provided by the invention, the broad-spectrum tolerance of the strain is improved, the methanol utilization capability of escherichia coli is remarkably enhanced while the tolerance of an intermediate toxic substrate formaldehyde is enhanced, and the TAL synthesis capability is remarkably enhanced while the tolerance to TAL is enhanced.

The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

Provided herein are methods for producing peptides from inclusion bodies. Also provided herein are onconase variants with improved properties.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a GUCY2C agonist. The invention also relates to test systems and cells that are suited to identify new candidate compounds for the treatment of Parkinson's disease.

The invention provides a pseudomonas aeruginosa engineering bacterium which is based on a PAO1 wild type strain, and two of the following genes, namely cyaA and cyaB, are knocked out from a genome at the same time. According to the pseudomonas aeruginosa engineering bacterium, the cyaA gene and the cyaB gene are knocked out at the same time, and the yield of rhamnolipid is remarkably increased on the premise that existing PAO1 fermentation process parameters and processes are not changed. The yield cannot be increased when the cyaA or the cyaB is singly knocked out, and the synergistic effect of double-gene knockout is proved.

Disclosed herein are nucleic acid constructs that can be used to build genetic circuits for producing antibodies comprising split toxins. Also disclosed herein are methods of producing platelets comprising the antibodies. The platelets produced by the methods disclosed herein can be used to target circulating tumor cells.

The present disclosure describes compositions and methods of treating solid tumors using chimeric antigen receptor (CAR) T cell (CAR-T) therapy and / or antibodies targeting uanylate Cyclase 2C (GCC. GUCY2C). The compositions include CAR comprising an extracellular domain that binds GCC. Further disclosed are methods of using modified T ceils expressing a CAR that binds GCC for treating different types of carters.

Provided is a fusion protein. The fusion protein simultaneously blocks a calcitonin gene-related peptide (CGRP) pathway and a pituitary adenylate cyclase-activating polypeptide (PACAP) pathway, wherein the fusion protein comprises at least one single-domain antibody, at least one Fc fragment, and at least one extracellular domain fragment of pituitary adenylate cyclase 1 (PAC1 ECD). The fusion protein can simultaneously block the CGRP and PACAP pathways, thereby improving the response rate of a drug for treatment of migraine.

Provided are an antigen-binding molecule specifically binding to GUCY2C and CD3 and pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor.

Provided are single domain antibodies that bind to GUCY2C, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.

Described herein are systems for measuring enzyme activity. Described herein are methods for measuring or screening enzyme activity utilizing the systems described herein.

Provided are a method for producing a target molecule on the basis of a condensation-segregation technique, a recombinant strain and the use thereof. By means of regulating the formation of biological condensates, high-concentration enrichment of target molecules at the cell end is achieved. By means of this step, highly-enriched target molecules are obtained and can be further accumulated by means of cell division. Compared with traditional methods, the method not only effectively improves the concentration of target molecules in a specific region within cells, but also realizes further accumulation of the enriched molecules by means of the mechanism of cell division.

Provided are an antigen-binding molecule specifically binding to GUCY2C and CD3 and pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor.

The present invention relates to a recombinant protein comprising one or more fragments of the surface protein A (PspA) of the pneumococcal, and an adenylate cyclase (CyaA) from the genus Bordetella, in particular Bordetella pertussis, in which the fragments of the PspA are selected from the group consisting of clades 1 to 4, or a combination of two or more thereof. Furthermore, the present invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, in particular a DNA sequence selected from the nucleotide sequences represented by SEQ ID NO: 12 to 18 and a degenerate sequence thereof, which respectively encode the recombinant protein represented by SEQ ID NO: 5 to 11. In addition, immunogenic compositions comprising the recombinant protein or the expression cassette and further pharmaceutically acceptable carriers and / or adjuvants are disclosed. Finally, the present invention relates to the use of said recombinant protein, said expression cassette or said immunogenic composition for the preparation of a vaccine for the prevention of infection by Streptococcus pneumoniae wherein said vaccine provides broad spectrum protection against different pneumococcal isolates regardless of serotypes.

Provided herein are expression constructs, viral genomes, and vectors for the expression of retinal membrane-bound guanylyl cyclase 1 (RetGC1), as well as pharmaceutical compositions comprising the vectors disclosed herein.Also provided are methods of using the expression constructs and vectors disclosed herein, including methods of treating a retinal disease in a subject in need thereof, the retinal disease being associated with one or more mutations in the GUCY2D gene, comprising administering to the subject the vectors disclosed herein.

The invention discloses a gene engineering strain with high yield of 3 '-deoxyadenosine and application of the gene engineering strain, and belongs to the technical field of gene engineering. The genetic engineering strain is obtained by carrying out genetic modification on the strain, and the genetic modification comprises at least one of the following steps: a) overexpressing a ribonucleotide reductase gene rnr1; b) inactivating / weakening an adenosine kinase gene ad1; c) inactivating / weakening the adenine deaminase gene aah1; d) overexpressing a ribonuclease gene rny1; and e) an inactivation / weakening inhibition type vacuolar alkaline phosphatase gene pho8. According to the method, substrate metabolism kinetics is accurately matched in combination with an intermittent feeding strategy, finally, the yield of 3 '-deoxyadenosine reaches 20.58 g / L and reaches the highest yield reported at present, a'gene-process' dual-drive technical barrier is formed, and an efficient, stable and low-cost solution is provided for industrial production of nucleoside compounds.

The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

The invention relates to an antigen binding molecule specifically binding to GUCY2C and CD3 and a medical application thereof. The antigen binding molecules can be used to treat tumors.

This disclosure relates to methods for increasing plant immunity or resistance to plant pathogens or pests, or inhibiting plant pathogens or pests, by supplying antimicrobial or antifungal oligopeptides. Antimicrobial or antifungal oligopeptides and nucleic acids encoding said oligopeptides are also provided herein. Compositions, kits, and cells comprising antimicrobial or antifungal oligopeptides are also provided.

Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent, methods, compositions and kits having a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a Botulinum toxin or an Anthrax toxin.

Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.

A fusion protein is provided that blocks both a calcitonin gene related peptide (CGRP) pathway and a pituitary adenylate cyclase activated peptide (PACAP) pathway, where the fusion protein comprises at least one single domain antibody, at least one Fc fragment, and at least one extracellular domain fragment of pituitary adenylate cyclase 1 (PAC1 ECD). The fusion protein can block CGRP and PACAP pathways at the same time, and the response rate of drugs for treating migraine is improved.

The invention discloses an application of a soybean RuBisCO activating enzyme family gene GmRCA11 in improvement of soybean quality. The nucleotide sequence of the soybean GmRCA11 protein coding gene GmRCA11 is shown as SEQ ID NO. 1, and the nucleotide sequence of the soybean GmRCA11 protein coding gene Genetic transformation is carried out on the PBA002-GmRCA11 overexpression vector in soybeans, and it is found that compared with a receptor Jack, the protein content in grains of an overexpression material is remarkably increased. Therefore, the soybean GmRCA11 protein coding gene GmRCA11 disclosed by the invention can be applied to the aspect of improving the soybean protein through genetic engineering.

Provided herein are expression constructs, viral genomes, and vectors for the expression of retinal membrane guanylyl cyclase 1 (RetGC1), as well as pharmaceutical compositions comprising the vectors disclosed herein. Also provided are methods of using the expression constructs and vectors disclosed herein, including methods of treating a retinal disease in a subject in need thereof, wherein the retinal disease is associated with one or more mutations in the GUCY2D gene, the method comprising administering to the subject a vector disclosed herein.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

Disclosed herein are methods that provide optimal conditions for site-specific digestion and mapping of the sequence of RNA polynucleotides using T2 family endoribonucleases, such as RNase MCI and Cusativin.

The invention relates to the technical field of biology, and discloses a GUCY2C polypeptide and application thereof. The GUCY2C polypeptide disclosed by the invention can be used for preparing an antibody.